ES2135458T3 - Sistema de medicamento que comprende una matriz de gel que contiene un farmaco inmobilizado. - Google Patents

Sistema de medicamento que comprende una matriz de gel que contiene un farmaco inmobilizado.

Info

Publication number
ES2135458T3
ES2135458T3 ES93901816T ES93901816T ES2135458T3 ES 2135458 T3 ES2135458 T3 ES 2135458T3 ES 93901816 T ES93901816 T ES 93901816T ES 93901816 T ES93901816 T ES 93901816T ES 2135458 T3 ES2135458 T3 ES 2135458T3
Authority
ES
Spain
Prior art keywords
immobilized
matrix containing
pharmacy
drug
gel matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93901816T
Other languages
English (en)
Inventor
Margaret Joan Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
De Montfort University
Original Assignee
De Montfort University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Montfort University filed Critical De Montfort University
Application granted granted Critical
Publication of ES2135458T3 publication Critical patent/ES2135458T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

SE PRESENTA UN METODO PARA PRODUCIR UN SISTEMA DE DROGA PARA SUMINISTRAR UNA DROGA PARA EL TRATAMIENTO DE UNA CONDICION, QUE CONSISTE EN PRODUCIR UNA MATRIZ BIOCOMPATIBLE QUE CONTIENE UNA DROGA INMOVILIZADA Y AL MENOS UN RECEPTOR PARA UNA SUSTANCIA FISIOLOGICA EN EL MEDIO DE LA MATRIZ, SIENDO ACTIVADO DICHO RECEPTOR EN RESPUESTA A LOS NIVELES DE DICHA SUSTANCIA FISIOLOGICA PARA EFECTUAR UN CAMBIO DE CONFORMACION EN LA MATRIZ QUE PERMITE LA MOVILIZACION Y LA LIBERACION DE LA DROGA DENTRO DEL MEDIO.
ES93901816T 1992-01-10 1993-01-08 Sistema de medicamento que comprende una matriz de gel que contiene un farmaco inmobilizado. Expired - Lifetime ES2135458T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929200638A GB9200638D0 (en) 1992-01-10 1992-01-10 Drug system

Publications (1)

Publication Number Publication Date
ES2135458T3 true ES2135458T3 (es) 1999-11-01

Family

ID=10708507

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93901816T Expired - Lifetime ES2135458T3 (es) 1992-01-10 1993-01-08 Sistema de medicamento que comprende una matriz de gel que contiene un farmaco inmobilizado.

Country Status (11)

Country Link
US (2) US5830506A (es)
EP (1) EP0626862B1 (es)
JP (1) JP4025363B2 (es)
AT (1) ATE183927T1 (es)
AU (1) AU3263093A (es)
DE (1) DE69326234T2 (es)
DK (1) DK0626862T3 (es)
ES (1) ES2135458T3 (es)
GB (1) GB9200638D0 (es)
GR (1) GR3031479T3 (es)
WO (1) WO1993013803A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii
GB9805896D0 (en) 1998-03-20 1998-05-13 Eglise David Remote analysis system
EP1212601A4 (en) * 1999-08-27 2006-03-29 Biotech Inc M glucose biosensor
WO2001081890A2 (en) * 2000-04-22 2001-11-01 M-Biotech, Inc. Hydrogel biosensor and biosensor-based health alarm system
GB0116860D0 (en) * 2001-07-10 2001-09-05 Univ Montfort Gel compositions
JP2005501096A (ja) 2001-08-17 2005-01-13 ユニヴァーシティ オブ ピッツバーグ 肥満、代謝症候群、糖尿病、血管障害及び腎臓疾患を治療又は予防するエストラジオールメタボライトの投与
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
US20080279936A1 (en) * 2001-10-10 2008-11-13 The University Of Pittsburgh Estradiol metabolites for reduction of endothelin production
US20090118605A1 (en) * 2002-08-30 2009-05-07 Northwestern University Surface-enhanced raman nanobiosensor
AU2003301064A1 (en) 2002-12-17 2004-07-14 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery
KR20050104383A (ko) * 2003-02-20 2005-11-02 유니버시티 오브 피츠버그 폐 고혈압의 치료를 위한 에스트라디올 대사물
US20060194775A1 (en) * 2003-02-20 2006-08-31 University Of Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
US7806856B2 (en) * 2005-04-22 2010-10-05 Accessclosure, Inc. Apparatus and method for temporary hemostasis
WO2007047922A2 (en) 2005-10-19 2007-04-26 Smartcells, Inc. Polymer-drug conjugates
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
CA2750223A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
JP2012516342A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 結晶性インスリン複合体
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
EP2408470A4 (en) 2009-03-20 2012-08-29 Smartcells Inc SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
EP2598170A4 (en) 2010-07-28 2016-07-06 Smartcells Inc MEDICINAL LIGANDEN CONJUGATES, THEIR SYNTHESIS AND INTERMEDIATE PRODUCTS THEREOF
US9068013B2 (en) 2010-07-28 2015-06-30 Smart Cells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
GB201314640D0 (en) 2013-08-15 2013-10-02 Univ Montfort Matrix gel
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3600381A4 (en) 2017-03-23 2021-06-16 Merck Sharp & Dohme Corp. GLUCOSE-ACTIVE INSULIN WITH A THREE-VALUE SUGAR CLUSTER FOR THE TREATMENT OF DIABETES
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
CN114432243B (zh) * 2022-01-20 2023-08-29 华南师范大学 一种响应pH和葡萄糖的纳米载体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348387A (en) * 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
ZA922425B (en) * 1991-04-02 1993-02-24 Biotech Australia Pty Ltd Oral delivery systems for microparticles
GB9200638D0 (en) 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii

Also Published As

Publication number Publication date
DK0626862T3 (da) 1999-12-13
US5830506A (en) 1998-11-03
WO1993013803A1 (en) 1993-07-22
GB9200638D0 (en) 1992-03-11
GR3031479T3 (en) 2000-01-31
EP0626862B1 (en) 1999-09-01
JPH07507268A (ja) 1995-08-10
DE69326234T2 (de) 1999-12-30
AU3263093A (en) 1993-08-03
ATE183927T1 (de) 1999-09-15
US20020168409A1 (en) 2002-11-14
DE69326234D1 (de) 1999-10-07
US7063863B2 (en) 2006-06-20
JP4025363B2 (ja) 2007-12-19
EP0626862A1 (en) 1994-12-07

Similar Documents

Publication Publication Date Title
ES2185654T3 (es) Sistema para la administracion de farmacos.
ES2060947T3 (es) Un nuevo sistema de suministro de anticuerpos para modificadores de la respuesta biologica.
ES2008580A6 (es) Forma de dosificacion para la liberacion rapida y lenta de agente beneficioso.
ES2059729T5 (es) Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
ES2038718T3 (es) Sistema terapeutico transdermal para la aplicacion de productos activos sobre la piel.
ES2039437T3 (es) Liberacion controlada de polipeptidos macromoleculares.
MX9207263A (es) Sistema para el suministro de una substancia activa para la liberacion sostenida.
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
ES2051882T3 (es) Composicion que comprende implantes oculares biodegradables.
WO2003077972A8 (en) Implantable drug delivery system
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ES2117146T3 (es) Tableta farmaceutica capaz de liberar una o varias sustancias medicamentosas a diferentes velocidades.
NO955361L (no) Organiske aerogeler
NO871774L (no) Medikament-system med kontrollert frisettelse av det aktive middel.
ECSP941148A (es) Medicamento en forma de comprimido con liberacion retardada de substancia activa
ES2081299T3 (es) Sistema para el suministro en ciclo cerrado de un agente simulador de ejercicio.
ES2037908T3 (es) Un procedimiento para la preparacion de una tableta de capas multiples en una forma de dosificacion unitaria solida.
ES2055067T3 (es) Microcapsula de liberacion retardada para farmaco soluble en agua.
FI875326A7 (fi) Valonsäteilyttäjälaite korvan lääketieteelliseen hoitoon.
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
ES2022454B3 (es) Sistema terapeutico para la liberacion controlada de drogas.
DE3863366D1 (de) Antibiotikum vermisporin, verfahren zu dessen herstellung und dasselbe als aktiver antibakterieller wirkstoff enthaltende pharmazeutische zusammensetzung.
GT199800152A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa.
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 626862

Country of ref document: ES